Article
Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome.
Anatolian journal of cardiology - 1 Apr 2017
García-Lagunar María Henar, Consuegra-Sánchez Luciano, Conesa-Zamora Pablo, Ruiz-Cosano Javier, Soria-Arcos Federico, García de Guadiana Luis, Vivar Pedro Cano, Castillo-Moreno Juan Antonio, Melgarejo-Moreno Antonio
Abstract excerpt
OBJECTIVE: To evaluate the contribution of six polymorphisms to the platelet reactivity in patients with acute coronary syndrome (ACS) treated with clopidogrel. METHODS: Cross-sectional study of 278 consecutive patients with ACS. Detailed clinical information for each patient was collected and genotypes (CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*17, CYP3A4*1B, and PON1-Q192R) were evaluated with TaqMan® and KASPar®...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
